Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
End-of-day quote. End-of-day quote Japan Exchange - 04/16
3704 JPY   -0.30%
04/14CENTOGENE N  : Extends Diagnostics Testing Partnership With Takeda
MT
04/08Japan shares slip on coronavirus concerns
RE
04/07Japan stocks fall on virus woes, but M&As lift some industrials
RE
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
04/12/2021 04/13/2021 04/14/2021 04/15/2021 04/16/2021 Date
3754 3716 3701 3715 3704 Last
4182300 6712800 5484000 3577800 4483900 Volume
+0.11% -1.01% -0.40% +0.38% -0.30% Change
Financials
Sales 2021 3 217 B 29 561 M 29 561 M
Net income 2021 262 B 2 410 M 2 410 M
Net Debt 2021 4 096 B 37 642 M 37 642 M
P/E ratio 2021 25,3x
Yield 2021 4,86%
Sales 2022 3 239 B 29 763 M 29 763 M
Net income 2022 368 B 3 385 M 3 385 M
Net Debt 2022 3 568 B 32 786 M 32 786 M
P/E ratio 2022 16,1x
Yield 2022 4,86%
Capitalization 5 795 B 53 250 M 53 257 M
EV / Sales 2021 3,07x
EV / Sales 2022 2,89x
Nbr of Employees 47 495
Free-Float 99,0%
More Financials
Company
Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - sale of services. Net sales are distributed geographically as follows: Japan (18%), Asia (5%), the... 
Sector
Pharmaceuticals
Calendar
05/11Earnings Release
More about the company
Notations Surperformance© of Takeda Pharmaceutical Company Limited
Trading Rating : Investor Rating :
More Ratings
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
04/14CENTOGENE N  : Extends Diagnostics Testing Partnership With Takeda
MT
04/08Japan shares slip on coronavirus concerns
RE
04/07Japan stocks fall on virus woes, but M&As lift some industrials
RE
04/07TAKEDA PHARMACEUTICAL  : to Host Wave 1 Pipeline Market Opportunity Conference C..
AQ
04/07KAMADA  : Amends GLASSIA License Contract with Takeda
MT
04/06STREET COLOR : Takeda Pharmaceutical Reportedly Suspends Development of Plasma T..
MT
04/05Japanese shares fall on profit booking, checking U.S. rates
RE
04/05SECTOR UPDATE : Health Care Stocks Scratch Out Slim Gains
MT
04/05UPDATE : Molecular Templates Scraps Experimental MT-3724 Drug, Takes Over Takeda..
MT
04/05SECTOR UPDATE : Health Care Stocks Advancing This Afternoon
MT
04/05TAKEDA PHARMACEUTICAL  : Molecular Templates to Take Over Takeda's Myeloma Treat..
MT
04/05Takeda Pharmaceutical Alliance's Clinical Trial Fails to Meet Endpoint
MT
04/05Japanese shares end higher on strong U.S. job data, SoftBank jumps
RE
04/04Japanese shares rise as strong U.S. job data lifts sentiment, index heavyweig..
RE
04/02TAKEDA PHARMACEUTICAL  : Topline Results from NIH-Sponsored Clinical Trial of In..
PU
More news
News in other languages on TAKEDA PHARMACEUTICAL COMPANY LIMITED
04/09Pump / dump #6
04/08TOKYO STOCK EXCHANGE : Borsa Tokyo chiude in calo su timori coronavirus
04/01TAKEDA PHARMACEUTICAL  : organiza una conferencia telefónica sobre sus productos..
04/01TAKEDA PHARMACEUTICAL  : veranstaltet Telefonkonferenz zu Marktchancen der Welle..
04/01TAKEDA PHARMACEUTICAL  : organise une téléconférence sur ses produits en dévelop..
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 5 197,86 JPY
Last Close Price 3 704,00 JPY
Spread / Highest target 86,3%
Spread / Average Target 40,3%
Spread / Lowest Target 10,7%
EPS Revisions
Managers and Directors
NameTitle
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Mwana Lugogo Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capitalization (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-1.36%53 452
JOHNSON & JOHNSON1.91%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.0.98%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-6.28%194 049